MaxCyte Inc
Change company Symbol lookup
Select an option...
MXCT MaxCyte Inc
MNTX Manitex International Inc
ACMR ACM Research Inc
DEA Easterly Government Properties Inc
NBSTU Newbury Street Acquisition Corp
UPS United Parcel Service Inc
BOLT Bolt Biotherapeutics Inc
EIX Edison International
EM Smart Share Global Ltd
WTW Willis Towers Watson PLC

Health Care : Biotechnology | Small Cap Growth
Company profile

MaxCyte, Inc. (MaxCyte) is a life sciences company. The Company is focused on advancing the discovery, development and commercialization of cell therapies. The Company provide cell-engineering platform to biopharmaceutical partners engaged in drug discovery and development, biomanufacturing and cell therapy, including gene editing and immuno-oncology. MaxCyte has developed and commercialized Flow Electroporation platform, which facilitates engineering of a wide variety of cells. The Company's ExPERT platform, which is based on Flow Electroporation technology, is designed to address the expanding cell therapy market, and used across the continuum of the cell therapy sector. The ExPERT family of products includes: three instruments, the ATx, STx and GTx. MaxCyte has also developed CARMA, a therapeutic platform based on transfecting mRNA into unstimulated cells for the development of immune cell therapies.

Closing Price
Day's Change
0.05 (0.83%)
B/A Size
Day's High
Day's Low

10-day average volume:



6 providers
January 24, 2022
MaxCyte Announces Strong Preliminary Unaudited Fourth Quarter and Full Year 2021 Revenue Results

-- Fourth quarter 2021 revenue expected to be greater than $10 million -- Full year 2021 revenue expected to be greater than $33.7 million -- Installed base of greater than 500 instruments -- 15 SPLs, covering more than 95 programs, of which over...(Globe Newswire)

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.